May 21, 2025, 08:22 | Science

Vivek Subbiah: Cancer Treatment Paradigms in The Precision Medicine Era

Vivek Subbiah, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute, posted on LinkedIn:…

May 21, 2025, 07:25 | Blog

Benedikt Westphalen Shares Final ESMO Recommendations for Molecular Tumour Boards

Benedikt Westphalen, Medical Lead of Precision Oncology at CCC München – Comprehensive Cancer Center, shared…

May 20, 2025, 14:10 | Science

Yakup Ergün: Denosumab and Zoledronic Acid in Advanced Breast Cancer patients

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared an article on X: "Zoledronic acid vs.…

May 12, 2025, 09:16 | Science

Goutham Sunny: TILs may serve as valuable Prognostic Biomarkers in HER2+ mBC

Goutham Sunny, Resident Doctor at The Gujarat Cancer and Research Institute, shared an article on X:…

May 8, 2025, 02:44 | Career

Eduard-Alexandru Bonci: Thrilled to share that I’ve been awarded at ESMO Merit Travel Grant

Eduard-Alexandru Bonci, Assistant Lecturer at University of Medicine and Pharmacy in Cluj-Napoca, posted on X:…

May 7, 2025, 15:53 | Blog

Giuseppe Curigliano and Barbara Jereczek-Fossa have been elected to lead ESMO and ESTRO - IEO European Institute of Oncology

IEO European Institute of Oncology shared a post on LinkedIn: "The multidisciplinary approach, based on…

May 7, 2025, 09:10 | Science

Circulating Tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Solid Tumors Treated with Neoadjuvant ICIs

Dana-Farber’s Breast Oncology Center shared a post on X: "Check out this recent Annals of…

May 5, 2025, 22:30 | Blog

Icro Meattini: Proud to co-chair ESMO-ESTRO session with Giuseppe Curigliano

Icro Meattini, Head of the Breast Unit at Florence University Hospital, posted on X: "Proud…

May 5, 2025, 09:34 | Science

Elvina Almuradova: From Dose-Finding to Dose-Optimization in Early-Phase Oncology Clinical Trials

Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared an article…

Apr 18, 2025, 14:07 | Blog

Humaid Al-Shamsi: Burjeel Cancer Institute signed an MoU with the European Institute of Oncology

Humaid Al-Shamsi, Founder and Director of Medical Oncology at Burjeel Medical City, shared a post…

Apr 14, 2025, 22:12 | Insight

Lorenzo Guidi: Bispecific Antibodies in Hematologic and Solid Tumors

Lorenzo Guidi, Medical Oncology Resident at the European Institute of Oncology (IEO), shared a post…

Apr 9, 2025, 08:51 | Drugs

Elvina Almuradova: Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Elvina Almuradova, Ambassador at European School of Oncology, shared an article Komal Jhaveri and her…

Apr 9, 2025, 07:16 | Blog

Vivek Subbiah: Key Recommendations for structuring Molecular Tumour Boards in clinical practice

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a LinkedIn post…

Apr 8, 2025, 15:46 | Science

Vivek Subbiah: Exploring the role of ctDNA Clearance as a Predictive Biomarker in Solid Tumors

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a…

Apr 8, 2025, 07:38 | Blog

Giuseppe Curigliano: ESMO Recommendations on Molecular Tumour Boards in Clinical Practice

Giuseppe Curigliano, Member of the Editorial Board for OncoDaily and President Elect of ESMO, posted…

Apr 7, 2025, 09:29 | Blog

Giuseppe Curigliano: ESMO Precision Oncology Working Group Quality and Structure Recommendations for MTBs

Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief, shared a LinkedIn post about recent…

Mar 16, 2025, 11:59 | Blog

SGBCC 2025 Highlights by Paolo Tarantino

The 19th St. Gallen International Breast Cancer Conference (SGBCC) took place from March 12–15, 2025,…

Mar 4, 2025, 07:35 | Blog

DESTINY-Breast07 phase Ib/II trial presented at ESMO TAT 2025

ESMO posted on LinkedIn: "Updated results presented at ESMO TAT 2025 from the DESTINY-Breast07 phase…

Feb 21, 2025, 10:55 | Blog

Giuseppe Curigliano: Mourning the untimely passing of Giovanni Scambia - a visionary leader in European gynecologic oncology

Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief, posted on LinkedIn: "We mourn the…

Feb 18, 2025, 07:54 | Blog

Giuseppe Curigliano: Maurizio Scaltriti - one of the most transformative oncologists of the last 30 years

Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief, shared a post on LinkedIn by…

Feb 16, 2025, 10:56 | Blog

The Second Global OncoThon: Highlights Part 3

OncoDaily and the International Society of Pediatric Oncology (SIOP) are hosting the Second Global OncoThon, a 24-hour virtual event on February 15, 2025,…

Feb 12, 2025, 08:43 | Blog

Carmine Valenza: The evolution of malignant phyllodes tumors of the breast

Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared an article he…

Feb 3, 2025, 10:46 | Science

Paolo Cotzia: Tucatinib and trastuzumab with fulvestrant for HR+ patients in heavily pretreated HER2-mut MBC

Paolo Cotzia, Medical Director of Molecular Pathology and Head of Molecular Excellence at Sonic Healthcare…

Feb 1, 2025, 12:52 | Oncologist Near Me

Oncologist Near Me – Giuseppe Curigliano: A Prominent Specialist in Breast Cancer Clinical Trials and Research

Welcome to OncoDaily's special section “Oncologist Near Me” where we introduce prominent oncologists from around the world.…

Feb 1, 2025, 08:22 | Blog

Carmine Valenza, a member of the 2024-2025 PCE Outreach Team - Program in Clinical Effectiveness

Program in Clinical Effectiveness shared a post on LinkedIn: "Meet Carmine Valenza, a member of…

Jan 31, 2025, 07:23 | Blog

Giuseppe Curigliano: Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer

Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief, shared on X: "Adding nivolumab to…

Jan 29, 2025, 17:41 | Insight

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Enhertu (trastuzumab deruxtecan), developed by AstraZeneca and Daiichi Sankyo has been approved by The FDA…

Jan 28, 2025, 15:01 | Insight

Breast Cancer Research Digest by Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X: "Check out the Breast Cancer Research Digest…

Jan 22, 2025, 18:49 | Insight

Breast Cancer Research Digest by Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X: “Here’s the most recent Breast Cancer…

Jan 20, 2025, 17:20 | Blog

Florian Lordick: Exploring the Pathway: New Insights in Gastrointestinal Oncology

Florian Lordick, Oncologist, Professor of Medicine at University of Leipzig, posted the following on LinkedIn:…

Jan 20, 2025, 13:34 | Blog

Great Debates and Updates in TNBC – Uniting Global Experts at BGICC 2025

BGICC-Breast Gynecological and Immunooncology International Cancer Conference shared a post on Facebook: "Great Debates and…

Jan 15, 2025, 17:48 | Insight

ESO announced the mentorship pairings for 2025

European School of Oncology (ESO) shared a post on Facebook: “We are pleased to announce…

Jan 14, 2025, 13:35 | Blog

Humaid Al-Shamsi: Two inspiring days with Giuseppe Curigliano at the European Institute of Oncology

Humaid Al-Shamsi, Founder and Director of Medical Oncology at Burjeel Medical City, posted on LinkedIn:…

Jan 11, 2025, 14:29 | Blog

Matthew Kurian: Highlights from San Antonio Breast Cancer Symposium 2024

Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine, shared…

Jan 5, 2025, 16:00 | Career

Giuseppe Curigliano: I have a new job position - ESMO President Elect

Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief shared a post on LinkedIn: "I…

Dec 22, 2024, 07:59 | Science

Ilana Schlam: The BRIDGES study is out

Ilana Schlam, Assistant Professor of Medicine at Tufts University Medical Center, shared on X about…

Dec 22, 2024, 05:00 | Blog

Elvina Almuradova: Being a part of Giuseppe Curigliano's team is an invaluable scientific milestone for me

Elvina Almuradova, Associate Professor at Medicana Health Group, shared a post on LinkedIn: "Being a…

Dec 21, 2024, 12:14 | Blog

Paolo Tarantino: Ending of a terrific 3-year cycle of PhD at The University of Milan

Paolo Tarantino, Research Fellow, Dana-Farber Cancer Institute, shared a post on LinkedIn: "Ending of a…

Dec 19, 2024, 16:53 | Blog

Giuseppe Curigliano: Great pleasure to host Prof. Humaid Al-Shamsi

Giuseppe Curigliano, Director of the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at…

Dec 13, 2024, 14:02 | Blog

Matthew Kurian: Day 2 at SABCS was one for the books

Matthew Kurian, Assistant Professor of medicine at the University of Kentucky College of Medicine, shared…

Dec 12, 2024, 16:50 | Insight

Imlunestrant and Abemaciclib: A Study in Advanced Breast Cancer

Imlunestrant has been approved for the treatment of breast cancer. It is a next-generation, brain-penetrant,…

Dec 12, 2024, 13:36 | Blog

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Erika Hamilton, The Director of Breast Cancer Program at Sarah Cannon Research Institute, shared on…

Dec 12, 2024, 13:26 | Insight

Highlights from Day 2 of SABCS 2024

The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…

Dec 5, 2024, 17:04 | Insight

Khalid El Bairi: The growing concerns about the emergence of non-peer-reviewed journals in oncology

Khalid El Bairi, Founder of The Cancer Biomarkers Working Group, shared a post on LinkedIn:…

Dec 5, 2024, 07:25 | Insight

Carmine Valenza: The Role of Germline BRCA Mutation in PARP Inhibitors-Related Hematologic Adverse Events

Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared a post on…

Dec 3, 2024, 13:09 | Insight

Khalid El Bairi: Our TASMAN study on the use of medical cannabis in oncology

Khalid El Bairi, Founder of The Cancer Biomarkers Working Group, shared a post on LinkedIn…

Nov 29, 2024, 19:46 | Insight

Evandro de Azambuja: Prevention of brain metastases in patients with HER2-positive breast cancer

Evandro de Azambuja, Director of Membership for the European Society for Medical Oncology (ESMO), shared…

Nov 29, 2024, 13:30 | Insight

Prevention of Brain Metastases HER2-positive Breast Cancer

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared a recent article by Volkmar…

Nov 29, 2024, 10:01 | Blog

Evandro de Azambuja: Improving ESMO's membership survey

Evandro de Azambuja, the Director of Membership for the European Society for Medical Oncology, posted…

Nov 22, 2024, 17:22 | Insight

Chiara Corti: Estrogen Signaling in Early-Stage Breast Cancer

Chiara Corti, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: “I am…

Nov 22, 2024, 16:51 | Blog

VHIO’s Josep Tabernero, Enriqueta Felip, and Ana Oaknin have been recognized as Clarivate Highly Cited 2024

Giuseppe Curigliano shared a post by Vall d’Hebron Institute of Oncology on X: "Congratulations Josep Tabernero , Enriqueta…

Nov 10, 2024, 13:41 | Blog

The most recent Breast Cancer Research Digest by Dana-Farber Cancer Institute

Dana-Farber’s Breast Oncology Center shared on X: "Check out the Breast Cancer Research Digest -…

Nov 4, 2024, 14:04 | Insight

Raffaele Colombo: Insights from October: Advances in ADC research and cancer therapeutics

Raffaele Colombo shared a post on LinkedIn: "October was extremely busy yet incredibly rewarding: With Jamie…

Nov 3, 2024, 15:49 | Blog

Paolo Cotzia: Investigating the role of immunotherapy in metastatic inflammatory breast cancer

Paolo Cotzia, Medical Director of Molecular Pathology and Head of Molecular Excellence at Sonic Healthcare…

Nov 2, 2024, 12:01 | Positive

Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

As Pink October has ended, it's time to reflect on Breast Cancer Awareness Month. OncoDaily…

Nov 2, 2024, 02:35 | Insight

Carmine Valenza: ICIs in patients with metastatic TN-IBC

Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared a post on…

Oct 30, 2024, 10:02 | Insight

Paper Alert ! Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer

Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer Authors: Chrysanthi Koukoutzeli, Dario…

Oct 29, 2024, 13:05 | Insight

Paolo Tarantino: My 100th scientific publication

Paolo Tarantino, Fellow at Dana-Farber Cancer Institute, shared a post on X: "It turns out…

Oct 25, 2024, 11:41 | Blog

Raffaele Colombo: Honored to discuss ADCs at the ENASymp24

Raffaele Colombo shared a post by Sandra Misale, Assistant professor at Sidney Kimmel Comprehensive Cancer…

Oct 22, 2024, 14:33 | Blog

Sebastian Szmit: Risk stratification and long-term follow-up proposed by ESC guidelines on cardiooncology

Sebastian Szmit shared a post by Monika Majewska, Editor, journalist, conference moderator at Pulse of…

Oct 18, 2024, 12:10 | Blog

From One-Size-Fits-All to Personalized Treatment: An article by Marleen Kok et al.

Maryam Lustberg shared on LinkedIn: "From One-Size-Fits-All to Personalized Treatment: Challenges and Potential Solutions. Opportunities…

Oct 13, 2024, 17:58 | Blog

Raffaele Colombo: Excited to be presenting ADCs at the 36th ENA symposium

The 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics will be held in person…

Oct 10, 2024, 16:44 | Blog

Giuseppe Curigliano: With T-DXd for HR-Positive Metastatic Breast Cancer

Giuseppe Curigliano shared an article on X: "DESTINY-Breast06 Shows Significant PFS Improvement With T-DXd for HR-Positive…

Oct 9, 2024, 16:03 | OncoDaily Pulse

Inside OncoDaily Party Barcelona

On September 13, 2024, OncoDaily Party took place at the Chiringuito Mokai Beach Bar in Barcelona, Spain.…

Oct 7, 2024, 16:33 | Blog

Lika Katselashvili: Developing combination therapies with biologics in TNBC

Lika Katselashvili shared on X: "Incredibly grateful for the amazing experience at IEO Milano under…

Oct 6, 2024, 17:29 | Blog

Lizzy Smyth: Privileged to co-chair the first ESMO ADC Advanced Course with Giuseppe Curigliano

Lizzy Smyth shared a post on X by Alberto Puccini, adding: "What a privilege to…

Oct 5, 2024, 09:20 | Insight

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors - ASCO

ASCO shared a post on X: "Experts Giuseppe Curigliano & Aditya Bardia discuss the results of…

Oct 2, 2024, 15:37 | Blog

Zainab Shinkafi-Bagudu: Chairing Nigeria's Cancer Network to Address Survivors' Needs

Zainab Shinkafi-Bagudu shared a post on Linkedin: ''I take my role as Chair of the…

Sep 23, 2024, 11:36 | Blog

OncoDaily Party Barcelona

On September 13, 2024, OncoDaily Party took place at the Chiringuito Mokai Beach Bar in…

Sep 20, 2024, 23:18 | Blog

Yüksel Ürun: Key goals post ESMO24

Yüksel Ürun shared a post on LinkedIn: "Key goals post ESMO24 1.Integrate findings into practice…

Sep 19, 2024, 11:07 | Blog

Elias Ortega Chahla: ESMO - YO Mentorship Session

Elias Ortega Chahla, Medical Director (Hematology/Oncology), IQVIA, shared a post on LinkedIn: "ESMO - YO…

Sep 19, 2024, 09:29 | Insight

Guilherme Nader Marta: DESTINY-Breast06 trial out in The New England Journal of Medicine

Guilherme Nader Marta, Advanced Clinical Fellow - Dana-Farber Cancer Institute, shared a post on LinkedIn: "DESTINY-Breast06…

Sep 19, 2024, 09:19 | Blog

Taha Koray Sahin: Inspiring and valuable mentorship session at ESMO24

Taha Koray Sahin shared a post on X: "Big thanks to Giuseppe Curigliano for the insightful…

Sep 18, 2024, 12:21 | Blog

Andrea Botticelli: Presenting the Rome trial results at ESMO 24 Presidential Session

Andrea Botticelli posted on LinkedIn: "What a great emotion to present the Rome trial results at…

Sep 18, 2024, 09:18 | Insight

34 Posts Not to Miss From ESMO24 Day 4

The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…

Sep 18, 2024, 00:08 | Insight

Paolo Tarantino: Testing T-DXd vs chemo for endocrine-refractory HR+ MBC

Paolo Tarantino shared a post on X: "Previously presented at ASCO24 by Giuseppe Curigliano, the impressive…

Sep 1, 2024, 15:03 | Blog

ESMO is seeking a new Editor-in-Chief to ESMO Open

ESMO - European Society for Medical Oncology shared a post on LinkedIn: "ESMO is seeking…

Aug 31, 2024, 16:51 | Insight

Vivek Subbiah: Future framework for Tissue agnostic drug development

Vivek Subbiah shared a post on LinkedIn: "Hot off the press, Presenting to the world a…

Aug 26, 2024, 20:01 | Blog

EU HTA Cooperation on ECO Community 365 Roundtable series

European Cancer Organisation (ECO) shared a post on LinkedIn: “A landmark piece of EU legislation…

Aug 22, 2024, 03:05 | Insight

Jarushka Naidoo: Excited to be a part of the Swiss Oncology Summer School

Jarushka Naidoo shared on LinkedIn: “Excited to be a part of the Swiss Oncology Summer…

Aug 18, 2024, 13:43 | Insight

ECO Community 365 Roundtable: EU HTA Regulation

European Cancer Organisation shared on LinkedIn: “A landmark piece of EU legislation to achieve greater…

Aug 18, 2024, 07:29 | Blog,Opinion

Paolo Tarantino: Do all patients with TNBC need 5 neoadjuvant drugs + 1 year of IO?

Paolo Tarantino shared a post on X about recent paper by Marleen Kok et al., titled…

Aug 10, 2024, 05:56 | Blog

Natacha Bolaños and Giuseppe Curigliano discuss EU legislation on HTA - ECO

European Cancer Organisation (ECO) shared on LinkedIn: "Are we ready for Joint Clinical Assessments? On…

Aug 5, 2024, 01:55 | Societies

Scientific Committees at the ESMO Congress 2024

The ESMO Congress is a globally influential oncology platform that brings together clinicians, researchers, patient…

Jul 31, 2024, 03:46 | Blog

ECO Community 365 Roundtable: HTA Regulation

European Cancer Organisation posted on LinkedIn: "A landmark piece of European Union legislation to achieve…

Jul 30, 2024, 12:17 | Blog

María Natalia Gandur Quiroga: Highlights from the article 'Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals'

María Natalia Gandur Quiroga posted on LinkedIn about recent paper by Irma Bisceglia et al., titled…

Jul 27, 2024, 22:17 | Insight

Commentary led by Marleen Kok highlights all questions in early TNBC post-KN522

Erika Hamilton shared on X: "This commentary led by Marleen Kok highlights all the pertinent…

Jul 26, 2024, 00:03 | Blog

Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522

Elisa Agostinetto shared on X: "Out in JCO a must-read by Marleen Kok on the…

Jul 25, 2024, 11:55 | Blog

European School of Oncology - The 2023 ESMO guidelines for early breast cancer diagnosis, treatment, and follow-up

European School of Oncology shared on LinkedIn: "Stay up-to-date with our e-Session 'The 2023 ESMO guidelines…

Jul 25, 2024, 08:58 | Insight

Marleen Kok: How do we get from one-size-fits-all to personalized treatment for TNBC

Marleen Kok, Breast Medical Oncologist at the Netherlands Cancer Institute, shared on X: "Today from…

Jul 25, 2024, 03:18 | Insight

6th and 7th ABC international consensus guidelines for the management of advanced breast cancer

ABC Global Alliance shared on LinkedIn: “Inequalities in access to care are a major hurdle…

Jul 24, 2024, 07:30 | Blog

European Union legislation on Health Technology Assessment - European Cancer Organisation

European Cancer Organisation shared a post on LinkedIn: ''A landmark piece of European Union legislation…

Jul 21, 2024, 10:33 | Blog

Filippo Montemurro: RWE of drug-drug interactions on abemaciclib

Filippo Montemurro, Senior Medical Director at F. Hoffmann La Roche, shared a post on X: "Clinical…

Jul 16, 2024, 05:54 | Blog

Unprecedented level of scientific discourse at INNOVATE

Hussein Tawbi, Professor at The University of Texas MD Anderson Cancer Center, shared a post…

Jul 15, 2024, 21:23 | Blog

Liz Burton: Humbling opportunity to co-chair the first International Neoadjuvant Immunotherapy Across Cancers in Naples

Liz Burton, Executive Director at UT MD Anderson Cancer Center, shared a post on X: …

Jul 15, 2024, 04:50 | Insight

Paolo Tarantino: Our article on ADCs is among the top 10 most cited in CA Cancer Journal

Paolo Tarantino, shared a post on LinkedIn about a recent paper titled "Antibody–drug conjugates: Smart…

Jul 6, 2024, 04:44 | Insight

The first meeting of our new Research Policy Network - ECO

European Cancer Organisation (ECO) shared on LinkedIn: “The first meeting of our new Research Policy…

Jul 3, 2024, 13:35 | OncoDaily Pulse

OncoDaily at ASCO 2024: OncoDaily Party, Yvonne Award and much more

OncoDaily at the Annual ASCO Conference 2024: A Comprehensive Report The American Society of Clinical…

Jul 3, 2024, 10:44 | Blog

Abeid M. Athman Omar: The last four months have been very eventful for me

Abeid M. Athman Omar, Clinical Oncology Specialist at Kenyatta University, shared a post on LinkedIn: "The last…

Jun 30, 2024, 10:58 | Insight

Eleonora Nicolò: Our analysis on safety and efficacy of new drugs investigated in phase I/II clinical trials by age

Eleonora Nicolò, Research Fellow at Weill Cornell Medicine, shared a post on X: "Just out…